Clinical Trial Update: Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the virological and immunological safety of a dose-reduction strategy for an efavirenz/tenofovir/emtricitabine antiretroviral regimen in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)
• Emtricitabine (Emtricitabine)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)

Snippet

Sponsor: Anna Cruceta | Conditions: HIV | Phase 4 | Status: COMPLETED | Results posted: 2025-07-18